SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

Location: Redwood City, CA

CIK: 0001910264 · Show all filings

Period: Q1 2023 (← Previous) (Next →)

Filing Date: May 19, 2023

Total Value: $268M (100.0% shares, 0.0% debt)

Holdings (6)

ACLX ARCELLX INC. 63.1%

Value $169M Shares 5,500,007 Est. Cost $16.72 Unrealized +81.4%

DSGN DESIGN THERAPEUTICS INC 14.0%

Value $37.66M Shares 6,526,476 Est. Cost $16.67 Unrealized -55.1%

MLYS MINERALYS THERAPEUTICS 10.5%

Value $28.1M Shares 1,794,600 Est. Cost $16.83 Unrealized 0.0%

SPRY ARS PHARMACEUTICALS 9.7%

Value $26.12M Shares 4,012,903 Est. Cost $6.79 Unrealized +13.2%

NKTX NKARTA INC. 1.8%

Value $4.733M Shares 1,333,333 Est. Cost $13.12 Unrealized -63.9%

— EFFECTOR THERAPEUTICS INC 0.9%

Value $2.388M Shares 6,822,114 Est. Cost $8.28 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC.	5,500,007	$169M	63.1%	$16.72	+81.4%	COMMON STOCK	03940C100
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$37.66M	14.0%	$16.67	-55.1%	COM	25056L103
MLYS	MINERALYS THERAPEUTICS	1,794,600	$28.1M	10.5%	$16.83	0.0%	COM	603170101
SPRY	ARS PHARMACEUTICALS	4,012,903	$26.12M	9.7%	$6.79	+13.2%	COM	82835W108
NKTX	NKARTA INC.	1,333,333	$4.733M	1.8%	$13.12	-63.9%	COM	65487U108
—	EFFECTOR THERAPEUTICS INC	6,822,114	$2.388M	0.9%	$8.28	—	COM	28202V108